AKBA יחס מהיר Akebia Therapeutics

Akebia Therapeutics (AKBA) generates revenue from the implementation of anemia therapies, with the drug Vafseo serving as the primary profit generator. However, geopolitical tensions and sanctions seriously hinder international logistics and the certification of new medications. Simultaneously, the company is fighting to maintain its positions in profitable market segments. This chart of the current market value on GURU.Markets confirms these trends, and the coefficient is 1.34.

FDA approval of Vafseo establishes a foundation for stable revenues for Akebia Therapeutics (AKBA), ensuring long-term patent protection. Analyzing the final quick ratio on the GURU.Markets platform, which equals 1.34, an investor can see the company's ability to cover short-term liabilities solely through cash and accounts receivable without relying on inventory, confirming the asset's high financial stability.